Skip to main content
SpringerLink
Log in

Clinical Applications for Immunohistochemistry of Breast Lesions

  • Protocol
  • First Online:
Breast Cancer

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1406))

  • 3287 Accesses

Abstract

Immunohistochemical analysis has been a key clinical tool that shows the protein expression of molecular markers. Expression of molecular markers in breast pathology has been used to distinguish breast cancers from benign lesions, classify subtypes of breast cancers, and determine therapeutic intervention. It is a relatively fast and efficient option in stratifying breast lesions to assist in both determining pathology diagnosis and offer strategies to the best course of clinical action. In this chapter, we discuss the use of immunohistochemistry testing for some of the key molecular markers involved in breast pathology that are crucial for classifying breast cancers and the guidelines for the interpretation of testing results that assist in clinical management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Collins LC, Schnitt SJ (2007) Histology for pathologists. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  2. Bocker W, Bier B, Freytag G, Brommelkamp B, Jarasch ED, Edel G, Dockhorn-Dworniczak B, Schmid KW (1992) An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II: epitheliosis and ductal carcinoma in situ. Virchows Arch A Pathol Anat Histopathol 421(4):323–330

    Article  PubMed  CAS  Google Scholar 

  3. Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ (1988) Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 19(3):276–289

    Article  PubMed  CAS  Google Scholar 

  4. Egan MJ, Newman J, Crocker J, Collard M (1987) Immunohistochemical localization of S100 protein in benign and malignant conditions of the breast. Arch Pathol Lab Med 111(1):28–31

    PubMed  CAS  Google Scholar 

  5. Werling RW, Hwang H, Yaziji H, Gown AM (2003) Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27(1):82–90

    Article  PubMed  Google Scholar 

  6. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C (2001) p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25(8):1054–1060

    Article  PubMed  CAS  Google Scholar 

  7. Damiani S, Ludvikova M, Tomasic G, Bianchi S, Gown AM, Eusebi V (1999) Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast. An immunocytochemical study. Virchows Arch 434(3):227–234

    Article  PubMed  CAS  Google Scholar 

  8. Lakhani S, Ellis I, Schnitt S (2012) WHO classification of tumours of the breast. IARC Press, Lyon

    Google Scholar 

  9. Tavassoli F, Devilee P (eds) (2003) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon

    Google Scholar 

  10. Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ (2001) Nuclear cytometric changes in breast carcinogenesis. J Pathol 193(1):33–39. doi:10.1002/1096-9896(2000)9999:9999<::AID-PATH744>3.0.CO;2-Q

    Article  PubMed  CAS  Google Scholar 

  11. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP (1998) Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast. Hum Pathol 29(12):1539–1545

    Article  PubMed  CAS  Google Scholar 

  12. Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP (1999) Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat 58(2):163–169

    Article  PubMed  CAS  Google Scholar 

  13. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3):146–151. doi:10.1056/NEJM198501173120303

    Article  PubMed  CAS  Google Scholar 

  14. Moinfar F, Man YG, Lininger RA, Bodian C, Tavassoli FA (1999) Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type – benign and malignant intraductal proliferations. Am J Surg Pathol 23(9):1048–1058

    Article  PubMed  CAS  Google Scholar 

  15. Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W (2000) Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 37(3):232–240

    Article  PubMed  CAS  Google Scholar 

  16. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, Herbst H, Schmidt A, Lerch MM, Buchwalow IB (2002) Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198(4):458–467. doi:10.1002/path.1241

    Article  PubMed  Google Scholar 

  17. Jain RK, Mehta R, Dimitrov R, Larsson LG, Musto PM, Hodges KB, Ulbright TM, Hattab EM, Agaram N, Idrees MT, Badve S (2011) Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol 24(7):917–923. doi:10.1038/modpathol.2011.66

    Article  PubMed  Google Scholar 

  18. Lacroix-Triki M, Mery E, Voigt JJ, Istier L, Rochaix P (2003) Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 442(6):548–554. doi:10.1007/s00428-003-0808-0

    PubMed  CAS  Google Scholar 

  19. Haagensen CD, Lane N, Lattes R, Bodian C (1978) Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 42(2):737–769

    Article  PubMed  CAS  Google Scholar 

  20. Jorns J, Sabel MS, Pang JC (2014) Lobular neoplasia: morphology and management. Arch Pathol Lab Med 138(10):1344–1349. doi:10.5858/arpa.2014-0278-CC

    Article  PubMed  Google Scholar 

  21. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23(24):5534–5541. doi:10.1200/JCO.2005.04.038

    Article  PubMed  Google Scholar 

  22. Zengel B, Yararbas U, Duran A, Uslu A, Eliyatkin N, Demirkiran MA, Cengiz F, Simsek C, Postaci H, Vardar E, Durusoy R (2013) Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast. Breast Cancer. doi:10.1007/s12282-013-0489-8

    PubMed  Google Scholar 

  23. Hofmeyer S, Pekar G, Gere M, Tarjan M, Hellberg D, Tot T (2012) Comparison of the subgross distribution of the lesions in invasive ductal and lobular carcinomas of the breast: a large-format histology study. Int J Breast Cancer 2012:436141. doi:10.1155/2012/436141

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ciocca RM, Li T, Freedman GM, Morrow M (2008) Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol 15(8):2263–2271. doi:10.1245/s10434-008-9960-8

    Article  PubMed  PubMed Central  Google Scholar 

  25. Korhonen T, Kuukasjarvi T, Huhtala H, Alarmo EL, Holli K, Kallioniemi A, Pylkkanen L (2013) The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast 22(6):1119–1124. doi:10.1016/j.breast.2013.06.001

    Article  PubMed  CAS  Google Scholar 

  26. Ferlicot S, Vincent-Salomon A, Medioni J, Genin P, Rosty C, Sigal-Zafrani B, Freneaux P, Jouve M, Thiery JP, Sastre-Garau X (2004) Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 40(3):336–341

    Article  PubMed  CAS  Google Scholar 

  27. Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156. doi:10.1186/bcr767

    Article  PubMed  PubMed Central  Google Scholar 

  28. Chan JK, Wong CS (2001) Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol 8(3):165–172

    Article  PubMed  CAS  Google Scholar 

  29. Ohkubo T, Ozawa M (1999) p120(ctn) binds to the membrane-proximal region of the E-cadherin cytoplasmic domain and is involved in modulation of adhesion activity. J Biol Chem 274(30):21409–21415

    Article  PubMed  CAS  Google Scholar 

  30. Nelson WJ, Nusse R (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303(5663):1483–1487. doi:10.1126/science.1094291

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Dabbs DJ, Kaplai M, Chivukula M, Kanbour A, Kanbour-Shakir A, Carter GJ (2007) The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol 15(3):260–266. doi:10.1097/01.pai.0000213128.78665.3c

    Article  PubMed  CAS  Google Scholar 

  32. Lerwill MF (2006) The evolution of lobular neoplasia. Adv Anat Pathol 13(4):157–165

    Article  PubMed  Google Scholar 

  33. Mastracci TL, Tjan S, Bane AL, O’Malley FP, Andrulis IL (2005) E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 18(6):741–751. doi:10.1038/modpathol.3800362

    Article  PubMed  CAS  Google Scholar 

  34. Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, Birchmeier W, Hofler H, Becker KF (1999) Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 18(30):4301–4312. doi:10.1038/sj.onc.1202790

    Article  PubMed  CAS  Google Scholar 

  35. Sarrio D, Perez-Mies B, Hardisson D, Moreno-Bueno G, Suarez A, Cano A, Martin-Perez J, Gamallo C, Palacios J (2004) Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 23(19):3272–3283. doi:10.1038/sj.onc.1207439

    Article  PubMed  CAS  Google Scholar 

  36. Davis BW, Gelber R, Goldhirsch A, Hartmann WH, Hollaway L, Russell I, Rudenstam CM (1985) Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 16(12):1212–1218

    Article  PubMed  CAS  Google Scholar 

  37. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G et al (1995) The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 76(10):1772–1778

    Article  PubMed  CAS  Google Scholar 

  38. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A, Goldhirsch A, Viale G (2005) Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 23(7):1379–1389. doi:10.1200/JCO.2005.07.094

    Article  PubMed  Google Scholar 

  39. Rosen PP (1983) Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu 18(Pt 2):215–232

    PubMed  Google Scholar 

  40. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA (2006) Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 94(11):1643–1649. doi:10.1038/sj.bjc.6603152

    PubMed  PubMed Central  Google Scholar 

  41. Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO (2007) Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 31(12):1825–1833. doi:10.1097/PAS.0b013e31806841f6

    Article  PubMed  Google Scholar 

  42. Treseler P (2006) Pathologic examination of the sentinel lymph node: what is the best method? Breast J 12(5 Suppl 2):S143–S151. doi:10.1111/j.1075-122X.2006.00328.x

    Article  PubMed  Google Scholar 

  43. Nasser IA, Lee AK, Bosari S, Saganich R, Heatley G, Silverman ML (1993) Occult axillary lymph node metastases in “node-negative” breast carcinoma. Hum Pathol 24(9):950–957

    Article  PubMed  CAS  Google Scholar 

  44. Mullenix PS, Brown TA, Meyers MO, Giles LR, Sigurdson ER, Boraas MC, Hoffman JP, Eisenberg BL, Torosian MH (2005) The association of cytokeratin-only-positive sentinel lymph nodes and subsequent metastases in breast cancer. Am J Surg 189(5):606–609. doi:10.1016/j.amjsurg.2005.01.031, discussion 609

    Article  PubMed  CAS  Google Scholar 

  45. Connolly JL (2006) Changes and problematic areas in interpretation of the AJCC Cancer Staging Manual, 6th Edition, for breast cancer. Arch Pathol Lab Med 130(3):287–291. doi:10.1043/1543-2165(2006)130[287:CAPAII]2.0.CO;2

    PubMed  Google Scholar 

  46. Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R (2004) Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 10(2):101–105

    Article  PubMed  Google Scholar 

  47. Carcoforo P, Bergossi L, Basaglia E, Soliani G, Querzoli P, Zambrini E, Pozza E, Feggi L (2002) Prognostic and therapeutic impact of sentinel node micrometastasis in patients with invasive breast cancer. Tumori 88(3):S4–S5

    PubMed  CAS  Google Scholar 

  48. Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, Hudis C, Borgen PI, Cody HS 3rd (2008) Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 26(11):1803–1809. doi:10.1200/JCO.2007.12.6425

    Article  PubMed  Google Scholar 

  49. Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG, Murray D, Pritchard KI, Sawka CA, McCready DR, Marks A (2006) Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 12(4):294–301. doi:10.1111/j.1075-122X.2006.00267.x

    Article  PubMed  Google Scholar 

  50. Czerniecki BJ, Scheff AM, Callans LS, Spitz FR, Bedrosian I, Conant EF, Orel SG, Berlin J, Helsabeck C, Fraker DL, Reynolds C (1999) Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 85(5):1098–1103

    Article  PubMed  CAS  Google Scholar 

  51. Clare SE, Sener SF, Wilkens W, Goldschmidt R, Merkel D, Winchester DJ (1997) Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 4(6):447–451

    Article  PubMed  CAS  Google Scholar 

  52. Lin F, Liu H (2014) Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. Arch Pathol Lab Med 138(12):1583–1610. doi:10.5858/arpa.2014-0061-RA

    Article  PubMed  Google Scholar 

  53. Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116(3):561–570. doi:10.1172/JCI27987

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  54. Jacobsen BM, Horwitz KB (2012) Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol 357(1–2):18–29. doi:10.1016/j.mce.2011.09.016

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  55. Harari D, Yarden Y (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19(53):6102–6114. doi:10.1038/sj.onc.1203973

    Article  PubMed  CAS  Google Scholar 

  56. Shah SS, Wang Y, Tull J, Zhang S (2009) Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma. Diagn Mol Pathol 18(1):30–33. doi:10.1097/PDM.0b013e31817c1af8

    Article  PubMed  CAS  Google Scholar 

  57. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093

    Article  PubMed  CAS  Google Scholar 

  58. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874. doi:10.1073/pnas.191367098

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  59. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418–8423. doi:10.1073/pnas.0932692100

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  60. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-0220

    Article  PubMed  CAS  Google Scholar 

  61. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264–271. doi:10.1038/modpathol.3800528

    Article  PubMed  CAS  Google Scholar 

  62. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. doi:10.1056/NEJMoa041588

    Article  PubMed  CAS  Google Scholar 

  63. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967

    Article  PubMed  Google Scholar 

  64. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. doi:10.1001/jama.295.21.2492

    Article  PubMed  CAS  Google Scholar 

  65. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32. doi:10.1002/cncr.22381

    Article  PubMed  CAS  Google Scholar 

  66. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-1109

    Article  PubMed  CAS  Google Scholar 

  67. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. doi:10.1200/JCO.2008.18.1370

    Article  PubMed  PubMed Central  Google Scholar 

  68. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101

    Article  PubMed  CAS  Google Scholar 

  69. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649. doi:10.1200/JCO.2007.11.6699

    Article  PubMed  CAS  Google Scholar 

  70. Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H (2013) Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. doi:10.1007/s12282-013-0474-2

    PubMed  Google Scholar 

  71. Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, Tokuda E, Shimizu H, Kosaka T, Saito M (2014) Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer 14:550. doi:10.1186/1471-2407-14-550

    Article  PubMed  PubMed Central  Google Scholar 

  72. Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schutt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S, West German Study Group (2008) Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19(5):861–870. doi:10.1093/annonc/mdm551

    Article  PubMed  CAS  Google Scholar 

  73. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD (1996) Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74(9):1445–1451

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  74. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89(2):111–117

    Article  PubMed  CAS  Google Scholar 

  75. Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12(15):4614–4618. doi:10.1158/1078-0432.CCR-06-0248

    Article  PubMed  CAS  Google Scholar 

  76. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 134(6):907–922. doi:10.1043/1543-2165-134.6.907

    PubMed  PubMed Central  Google Scholar 

  77. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr, American Society of Clinical Oncology (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. doi:10.1200/JCO.2007.14.2364

    Article  PubMed  CAS  Google Scholar 

  78. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical Oncology; College of American Pathologists (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984

    Article  PubMed  Google Scholar 

  79. Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E (2004) Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61(23):2965–2978. doi:10.1007/s00018-004-4277-7

    Article  PubMed  CAS  Google Scholar 

  80. Ellis IO, Elston CW (2006) Histologic grade. Elsevier, Philadelphia

    Book  Google Scholar 

  81. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26(19):3153–3158. doi:10.1200/JCO.2007.15.5986

    Article  PubMed  Google Scholar 

  82. Harris GC, Denley HE, Pinder SE, Lee AH, Ellis IO, Elston CW, Evans A (2003) Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol 27(1):11–15

    Article  PubMed  Google Scholar 

  83. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA (1998) The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer 83(8):1529–1539

    Article  PubMed  CAS  Google Scholar 

  84. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.1093/jnci/djp082

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  85. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working Group (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664. doi:10.1093/jnci/djr393

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  86. Yu CC, Woods AL, Levison DA (1992) The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochem J 24(3):121–131

    Article  PubMed  CAS  Google Scholar 

  87. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Trialists I (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11(2 Pt 2):951s–958s

    PubMed  CAS  Google Scholar 

  88. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63(19):6523–6531

    PubMed  CAS  Google Scholar 

  89. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R (2012) The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 25(8):1098–1105. doi:10.1038/modpathol.2012.59

    Article  PubMed  CAS  Google Scholar 

  90. Kalkman S, Barentsz MW, van Diest PJ (2014) The effects of under 6 hours of formalin fixation on hormone receptor and HER2 expression in invasive breast cancer: a systematic review. Am J Clin Pathol 142(1):16–22. doi:10.1309/AJCP96YDQSTYBXWU

    Article  PubMed  Google Scholar 

  91. Arber DA (2002) Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol 10(2):183–186

    PubMed  Google Scholar 

  92. Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J (2007) The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer 14(2):182–188

    Article  PubMed  Google Scholar 

  93. Tong LC, Nelson N, Tsourigiannis J, Mulligan AM (2011) The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. Am J Surg Pathol 35(4):545–552. doi:10.1097/PAS.0b013e31820e6237

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

The authors would like to thank Ms. Laura Birney, Lucille Camille Kutcher, and Julie Elder of the Histology Laboratory at the Stony Brook University Hospital for their technical assistance.

Author information

Authors and Affiliations

  1. Department of Pathology, Stony Brook University Hospital, Stony Brook, NY, USA

    Kester Haye, Rajarsi Gupta & Christopher Metter

  2. Associate Professor of Pathology, Department of Pathology, Stony Brook University Hospital, Stony Brook, NY, 11794-7025, USA

    Jingxuan Liu

Authors
  1. Kester Haye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajarsi Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher Metter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingxuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jingxuan Liu .

Editor information

Editors and Affiliations

  1. School of Medicine, Stony Brook University, Stony Brook, New York, USA

    Jian Cao

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Haye, K., Gupta, R., Metter, C., Liu, J. (2016). Clinical Applications for Immunohistochemistry of Breast Lesions. In: Cao, J. (eds) Breast Cancer. Methods in Molecular Biology, vol 1406. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3444-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3444-7_2

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3442-3

  • Online ISBN: 978-1-4939-3444-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation